H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Scotiabank Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $40
Beam Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
Beam Therapeutics' BEAM-302: Promising Clinical Data and Market Potential Drive Buy Rating
RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Cuts Target Price to $20
RBC Cuts Price Target on Beam Therapeutics to $20 From $26, Keeps Sector Perform, Speculative Risk
Clear Street Initiates Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $34
BofA Securities Upgrades Beam Therapeutics(BEAM.US) to Buy Rating, Maintains Target Price $42
B of A Securities Upgrades Beam Therapeutics to Buy, Maintains Price Target to $42
Beam Therapeutics Analyst Ratings
Bernstein Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $37
Citi Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $64
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Beam Therapeutics (BEAM)
Promising BEAM-302 Trial Results and Strong Financial Position Support Buy Rating for Beam Therapeutics
Beam Therapeutics: Promising Phase 1 Results for BEAM-302 in AATD, Hold Rating Due to Long-term Efficacy Uncertainty
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $34 to $80
Beam Therapeutics Raised to Buy From Hold by Jones Trading
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Beam Therapeutics Analyst Ratings